Markets:

Overview

News

Currencies

International

Treasuries

CRISPR Therapeutics AG - Common Shares (NQ:CRSP)

54.67 -1.71 (-3.03%)

Streaming Delayed Price Updated: 11:03 AM EDT, May 29, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about CRISPR Therapeutics AG - Common Shares

< Previous 1 2

...

15 16 17 18 19 20 21 22 23

...

36 37 Next >

Better Gene Editing Stock: Editas Medicine vs. CRISPR Therapeutics ↗

October 02, 2023

The better of the pair should be able to beat Bluebird Bio.

Via The Motley Fool

3 Revolutionary Stocks I'd Buy Right Now Without Hesitation ↗

October 01, 2023

These companies are helping change medicine; they could make boatloads of money along the way.

Via The Motley Fool

3 Cathie Wood Stocks Set to Explode Higher ↗

October 01, 2023

Delve into the exciting world of Cathie Wood Stocks where potential meets performance, offering investors hefty long-term upside.

Via InvestorPlace

Futurescape: Betting Big on These 3 Next-Gen Tech Stocks ↗

October 01, 2023

These next-gen tech stocks that emphasize forward-thinking innovation are perfect for investors who seek big bets or massive gains.

Via InvestorPlace

3 No-Brainer Growth Stocks to Buy in October ↗

October 01, 2023

These three top mid-cap stocks could be poised for a long-tailed growth spurt.

Via The Motley Fool

Editas Medicine Is Beyond Skepticism, Analyst Has Confidence In Sickle Cell Therapy, Upgrades Stock ↗

September 29, 2023

Stifel has upgraded Editas Medicine Inc (NASDAQ: EDIT), saying the company's sickle cell disease candidate, EDIT-301's progress, has received minimal credit from investors.

Via Benzinga

2 Bargain Growth Stocks to Buy Hand Over Fist ↗

September 28, 2023

Both stocks have declined in recent times.

Via The Motley Fool

2 No-Brainer Biotech Stocks to Buy Right Now ↗

September 12, 2023

You can get in early on these potential winners.

Via The Motley Fool

Why Editas Medicine Stock Is Soaring Today ↗

September 29, 2023

Investors are cheering a big analyst upgrade for the gene-editing stock.

Via The Motley Fool

If I Could Only Buy 3 Stocks in 2023, I'd Pick These ↗

September 29, 2023

These stocks have what it takes to grow in leaps and bounds.

Via The Motley Fool

Crispr Therapeutics, And CRISPR Gene-Editing, Face Their Make-Or-Break Moment ↗

September 28, 2023

The FDA is within three months of making a decision on the first-ever CRISPR-based drug.

Via Investor's Business Daily

Don’t Miss the Boom: 3 Pharma Stocks Set to Explode Higher ↗

September 27, 2023

These pharma stocks could boom in the coming years, riding their diversified pipelines with massive addressable markets higher.

Via InvestorPlace

From Dust to Diamonds: 7 Undervalued Stocks With Sparkling Prospects ↗

September 27, 2023

Are you looking to invest in undervalued stocks? Here are sever undervalued stocks with sparkling prospects.

Via InvestorPlace

Benzinga's Top Ratings Upgrades, Downgrades For September 27, 2023 ↗

September 27, 2023

Via Benzinga

Are Gene Therapy Stocks The Market's Next Big Winners?

September 25, 2023

Biotechs Sarepta and BioMarin are among companies advancing cutting-edge gene therapies, although those treatments can come with a $2 million or more price.

Via MarketBeat

Topics Artificial Intelligence

2 Cathie Wood Stocks to Buy Hand Over Fist Right Now ↗

September 24, 2023

These two high-tech stocks could dramatically outperform the broader market in the years ahead.

Via The Motley Fool

$10,000 Invested in These Growth Stocks Could Make You a Fortune Over the Next 10 Years ↗

September 21, 2023

I favor holding onto these players for the long term to truly benefit from their earnings potential.

Via The Motley Fool

Better Growth Stock: CRISPR Therapeutics vs. Bluebird Bio ↗

September 20, 2023

These two biotechs have a lot in common, but one is much better capitalized.

Via The Motley Fool

Flee to Healthcare Stocks if Recession Rears its Head?

September 20, 2023

In uncertain economic conditions, healthcare stocks can be a refuge due to steady demand and favorable inflation conditions. Many also offer dividends.

Via MarketBeat

Topics Economy

Where Will CRISPR Therapeutics Be in 5 Years? ↗

September 19, 2023

The company hasn't performed well in the past five years, but things could change.

Via The Motley Fool

1 Huge Risk That Gene-Editing Stock Investors Desperately Need to Know ↗

September 19, 2023

Good medicines aren't always good business.

Via The Motley Fool

2 Top Trends to Invest $500 In Right Now ↗

September 18, 2023

Early investors in these trends may reap the rewards over time.

Via The Motley Fool

Looking for Growth? These Companies' Revenue May Skyrocket ↗

September 17, 2023

Catalysts on the horizon could drive gains in these top stocks.

Via The Motley Fool

If You Invested $30,000 in CRISPR Therapeutics in 2016, This Is How Much You Would Have Today ↗

September 16, 2023

The returns are impressive, but will they continue to be so?

Via The Motley Fool

Better Growth Stock: Recursion Pharmaceuticals vs. CRISPR Therapeutics ↗

September 15, 2023

They're both liable to grow by a lot, but one of them is a safer bet in the near term.

Via The Motley Fool

Have Million-Dollar Gene Therapies Finally Reached An Inflection Point? ↗

September 15, 2023

Gene therapies are clearing the FDA and reaching seriously ill patients. They could cost millions.

Via Investor's Business Daily

3 Top Healthcare Stocks Defying the Bear Market ↗

September 15, 2023

Revenue at all three companies improved last quarter, and their share prices have followed suit.

Via The Motley Fool

Better Bull Market Buy: CRISPR vs. Medtronic Stock ↗

September 14, 2023

Investors may look for growth stocks ahead of the next bull market.

Via The Motley Fool

3 Biotech Blockbusters to Turn $5,000 Into $50,000 ↗

September 12, 2023

These transformative early-stage biotech stocks can deliver triple-digit upside if their key milestones are achieved on time.

Via InvestorPlace

More Likely to 5x First: Bluebird Bio vs. CRISPR Therapeutics ↗

September 12, 2023

These companies are innovators, something that can prove highly lucrative.

Via The Motley Fool

< Previous 1 2

...

15 16 17 18 19 20 21 22 23

...

36 37 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.